6533b85efe1ef96bd12bfd9f

RESEARCH PRODUCT

Limited agreement between biomarkers of neuronal injury at different stages of Alzheimer's disease

Timo GrimmerStefan FörsterLaura KriettKatherine R. GrayAndreas FellgiebelPanagiotis AlexopoulosPanagiotis AlexopoulosAlexander DrzezgaNikolaos A. LaskarisRobert PerneczkyRobert PerneczkyAlexander KurzBernhard HallerIgor YakushevElisabeth Klupp

subject

MalePathologymedicine.medical_specialtyEpidemiologytau ProteinsHippocampus03 medical and health sciencesCellular and Molecular NeuroscienceApolipoproteins E0302 clinical medicineAtrophyCerebrospinal fluidDevelopmental NeuroscienceNeuroimagingAlzheimer DiseaseFluorodeoxyglucose F18medicineHumansDementiaCognitive DysfunctionAged030304 developmental biology0303 health sciencesChi-Square Distributionmedicine.diagnostic_testHealth PolicyMiddle Agedmedicine.diseasePsychiatry and Mental healthPositron emission tomographyPositron-Emission TomographyBiomarker (medicine)FemaleNeurology (clinical)AtrophyGeriatrics and GerontologyAlzheimer's diseaseMental Status SchedulePsychologyChi-squared distributionBiomarkers030217 neurology & neurosurgery

description

Abstract New diagnostic criteria for Alzheimer's disease (AD) treat different biomarkers of neuronal injury as equivalent. Here, we quantified the degree of agreement between hippocampal volume on structural magnetic resonance imaging, regional glucose metabolism on positron emission tomography, and levels of phosphorylated tau in cerebrospinal fluid (CSF) in 585 subjects from all phases of the AD Neuroimaging Initiative. The overall chance-corrected agreement was poor (Cohen κ, 0.24–0.34), in accord with a high rate of conflicting findings (26%–41%). Neither diagnosis nor APOE e4 status significantly influenced the distribution of agreement between the biomarkers. The degree of agreement tended to be higher in individuals with abnormal versus normal CSF β-amyloid (Aβ 1-42 ) levels. Prospective diagnostic criteria for AD should address the relative importance of markers of neuronal injury and elaborate a way of dealing with conflicting biomarker findings.

yearjournalcountryeditionlanguage
2013-11-21Alzheimer's & Dementia
https://doi.org/10.1016/j.jalz.2014.03.006